Akebia Therapeutics (AKBA) Other Non-Current Assets (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Other Non-Current Assets of $56.6 million for Q1 2026, up 47.55% year-over-year from $38.3 million in Q1 2025, and down 5.21% quarter-over-quarter from $59.7 million in Q4 2025.
Akebia Therapeutics (AKBA) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Other Non-Current Assets for 14 consecutive years, with $56.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 47.55% year-over-year to $56.6 million; the TTM figure through Mar 2026 stood at $56.6 million (up 47.55% YoY), while the FY2025 annual figure was $59.7 million, up 59.67% from the prior year.
- Other Non-Current Assets slipped to $56.6 million in Q1 2026 per AKBA's latest filing, from $59.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $59.7 million in Q4 2025 and bottomed at $3.3 million in Q2 2023.
- Historically, Other Non-Current Assets has averaged $27.3 million across 5 years, with a median of $27.1 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets tumbled 90.42% — and 2024, when it surged 602.59%.
- Akebia Therapeutics' Other Non-Current Assets stood at $5.4 million in 2022, then soared by 131.25% to $12.4 million in 2023, then soared by 200.87% to $37.4 million in 2024, then jumped by 59.67% to $59.7 million in 2025, then dropped by 5.21% to $56.6 million in 2026.
- Business Quant data shows AKBA's Other Non-Current Assets at $56.6 million in Q1 2026, $59.7 million in Q4 2025, and $40.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 13.00 Mn |
| 10 | Akebia Therapeutics | 247.60 Mn | 92.06 Mn | 38.70 Mn | 53.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.75 Mn |
| Mar 31, 2026 | 56.57 Mn |
| Dec 31, 2025 | 59.68 Mn |
| Sep 30, 2025 | 40.46 Mn |
| Jun 30, 2025 | 44.19 Mn |
| Mar 31, 2025 | 38.34 Mn |
| Dec 31, 2024 | 37.38 Mn |
| Sep 30, 2024 | 27.13 Mn |
| Jun 30, 2024 | 17.78 Mn |
| Mar 31, 2024 | 11.79 Mn |
| Dec 31, 2023 | 12.42 Mn |
| Sep 30, 2023 | 3.86 Mn |
| Jun 30, 2023 | 3.35 Mn |
| Mar 31, 2023 | 5.24 Mn |
| Dec 31, 2022 | 5.37 Mn |
| Sep 30, 2022 | 25.94 Mn |
| Jun 30, 2022 | 34.95 Mn |
| Mar 31, 2022 | 39.42 Mn |
| Dec 31, 2021 | 50.42 Mn |
| Sep 30, 2021 | 69.60 Mn |